Radius Health To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
WALTHAM, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that Chief Commercial Officer, David Snow, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 at 1:00 p.m. EDT at Le Parker Meridien Hotel in New York, NY.
About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe, and a New Drug Application (NDA) has been accepted for filing by the FDA. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.
- Health Care Industry
- osteoporosis
Investor Relations Contact:
Barbara Ryan
Email: bryan@radiuspharm.com
Phone: 203-274-2825
Media Contact:
Lori Gorski
Email: lgorski@radiuspharm.com
Phone: 617-551-4096